[144] Royalty Pharma plc SEC Filing

Rhea-AI Filing Summary

Royalty Pharma plc submitted a Form 144 proposing the sale of 33,500 Class A ordinary shares through Merrill Lynch on NASDAQ, with an approximate sale date of 08/11/2025. The filing lists an aggregate market value of $1,213,747.00 and 432,293,050 shares outstanding, so the proposed block represents a very small fraction of the company.

The shares were acquired on 04/13/2015 in an exchange of limited partnership interests from Royalty Pharma plc, with cash payment recorded. The filer reports no securities sold in the past three months and includes the standard representation that no material nonpublic information is known.

Positive

• Proposed sale size is small: 33,500 shares representing approximately 0.0078% of 432,293,050 shares outstanding
• No sales in past three months: the form reports "Nothing to Report" for securities sold during the prior 3 months
• Clear acquisition history provided: shares were acquired on 04/13/2015 in an exchange of limited partnership interests with payment in cash

Negative

• None.

Insights

Securities Analyst

TL;DR: Small Rule 144 proposed sale; unlikely to move market given size relative to outstanding shares.

The filing shows a proposed sale of 33,500 shares valued at $1,213,747 versus 432,293,050 shares outstanding, representing roughly 0.0078% of the share base. Because the block is immaterial to total capitalization, market impact should be limited. The details provided (broker, exchange, acquisition date and nature) are standard for a Form 144 and allow market participants to time and route orders appropriately.

Compliance/Risk Analyst

TL;DR: Form 144 contains required disclosures and a representation about material nonpublic information; no recent sales reported.

The filer discloses acquisition on 04/13/2015 via an exchange of limited partnership interests and payment in cash, and notes "Nothing to Report" for sales in the prior three months. The submission identifies the executing broker and exchange, and includes the standard signer representation required under Rule 144, fulfilling routine compliance expectations for an intended sale under the rule.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Merrill Lynch 225 Liberty St Floor 37 New York NY 10281	33500	1213747.00	432293050	08/11/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	04/13/2015	Exchange of limited partnership interests	Royalty Pharma plc			33500	04/13/2015	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks

Date of Notice

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does Royalty Pharma's (RPRX) Form 144 report?

The filing proposes the sale of 33,500 Class A ordinary shares via Merrill Lynch on NASDAQ, with an approximate sale date of 08/11/2025 and aggregate market value of $1,213,747.00.

How large is the proposed sale relative to outstanding shares for RPRX?

The form lists 432,293,050 shares outstanding; 33,500 shares represent about 0.0078% of the outstanding share count.

When and how were the shares being sold acquired?

The shares were acquired on 04/13/2015 in an exchange of limited partnership interests from Royalty Pharma plc, with payment in cash.

Has the filer sold any Royalty Pharma securities in the prior three months?

No. The filing states "Nothing to Report" for securities sold during the past three months.

Which broker and market are named for the proposed sale?

The executing broker is listed as Merrill Lynch, 225 Liberty St Floor 37, New York, NY, and the sale is designated for NASDAQ.